This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents — quick navigation | ||
|---|---|---|
| A | Basic information | ICD-10: G41.0 | Special Copayment Reduction: V125 | Coverage period: 5 years |
| B | Synonyms | Tonic-clonic status epilepticus, grand mal status epilepticus, convulsive status epilepticus (CSE) |
| C | Adult onset | Occurs frequently in adults; stroke, brain tumors, alcohol withdrawal and discontinuation of antiseizure medications are the main causes in adults |
| S1 | History | Evolution of the SE concept and the change from a 30-minute to a 5-minute criterion |
| S2 | Causes | Discontinuation of antiseizure medications, stroke, encephalitis, metabolic abnormalities, alcohol withdrawal, etc. |
| S3 | Genetics | Genetic predisposition (SCN1A, etc.), associated with specific epilepsy syndromes |
| S4 | General epidemiology | Annual incidence 10–41/100,000; mortality ~20% |
| S5 | Pathophysiology | Failure of seizure termination mechanisms; GABA receptor internalization; glutamate hyperactivity |
| S6 | Symptoms | Tonic phase → clonic phase → postictal coma; 5 minutes or longer or recurrent seizures |
| S7 | Signs | Continuous convulsions, acidosis, hyperthermia, rhabdomyolysis, continuous discharges on EEG |
| S8 | Screening | Blood glucose, electrolytes, AED blood levels, toxicology screen, EEG |
| S9 | Diagnosis | Clinical diagnosis; 5-minute criterion; tests to identify the cause |
| S10 | Treatment | Lorazepam → fosphenytoin/valproate/levetiracetam → anesthetics |
| S11 | Prognosis | Mortality 10–20%; morbidity: brain damage, cognitive impairment, risk of recurrence |
| S12 | Prevention | Adherence to antiseizure medications, management of triggers, early treatment of fever |
| S13 | References | 10 key references |
Medical descriptions of status epilepticus (SE) are found even in ancient Egyptian and Babylonian texts, but the modern concept was formed in the 19th century. In 1824, Louis-Florentin Calmeil first used the term "état de mal épileptique" (epileptic state), and in 1876 William Richard Gowers systematically described the clinical features of grand mal SE.
Initially, SE was defined as "a seizure lasting 30 minutes or longer, or two or more recurrent seizures without recovery of consciousness between seizures". This 30-minute criterion was based on the point at which permanent brain damage occurs in animal models. However, as epidemiological evidence accumulated that tonic-clonic seizures lasting 5 minutes or longer clinically rarely terminate on their own, the ILAE revised the definition of SE in 2015.
In 2015, the ILAE Task Force defined SE as "a condition resulting from failure of seizure termination mechanisms or abnormally prolonged seizures, applying two time points (T1: time to start treatment, T2: time at which long-term consequences may occur)". For tonic-clonic SE, T1 (start of treatment) was set at 5 minutes and T2 (risk of long-term damage) at 30 minutes. With this revision, recommendations to start treatment immediately in clinical practice when convulsions persist for 5 minutes or longer were strengthened.
In the history of treatment, important milestones were the introduction of intravenous barbiturates in the 1950s–60s, diazepam in the 1970s and lorazepam in the 1990s. In 2001, the Veterans Affairs Status Epilepticus Cooperative Study (VA SECS) demonstrated that lorazepam had equal or superior efficacy compared with the diazepam + phenytoin combination.
The causes of tonic-clonic SE are classified as acute symptomatic, remote symptomatic, progressive, and idiopathic/cryptogenic.
| Cause category | Specific causes | Relative frequency |
|---|---|---|
| Discontinuation of/nonadherence to antiseizure medications | Abrupt drug discontinuation, low blood levels | Very common |
| Stroke | Ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage | Common |
| Metabolic abnormalities | Hypoglycemia, hyponatremia, hypocalcemia, uremia, hepatic encephalopathy | Common |
| Alcohol withdrawal | Upon withdrawal in chronically alcohol-dependent individuals | Common |
| Encephalitis/meningitis | Viral, bacterial, autoimmune encephalitis (NMDA-R Ab, etc.) | Moderate |
| Drug toxicity | Tricyclic antidepressants, isoniazid, lithium, cocaine, etc. | Moderate |
| Brain tumors | Primary and metastatic brain tumors | Moderate |
| Head trauma | Acute and subacute post-traumatic epilepsy | Moderate |
Tonic-clonic SE itself is not a specific genetic disease, but genetic predisposition influences the risk of developing SE.
From a pharmacogenomic perspective, CYP2C9 and CYP2C19 polymorphisms affect phenytoin metabolism and may be related to the efficacy of SE treatment. The HLA-B*15:01 and HLA-A*31:01 alleles are associated with the risk of severe carbamazepine-related skin reactions.
Genome-wide association studies (GWAS) have found several loci associated with SE susceptibility, but clinical application is still limited.
The annual incidence of all SE, including tonic-clonic SE, is estimated at 10–41 per 100,000 population, varying by region and study method. In the United States, about 150,000 cases of SE occur annually, a substantial proportion of which are tonic-clonic SE.
Incidence shows a bimodal pattern in its age distribution: it is high in infants under 1 year of age and in older adults aged 60 years or older. A slightly higher incidence is observed in males. The mortality of all SE is about 10–22%, and that of tonic-clonic SE is about 7–20%. Mortality varies greatly depending on the severity of the underlying disease, patient age and duration of SE.
Prognostic tools such as the Status Epilepticus Severity Score (STESS) and the Epidemiology-Based Mortality Score in Status Epilepticus (EMSE) have been developed and are used in clinical practice. In Korea, the incidence of SE is estimated from data on emergency department visits and hospitalizations of patients with epilepsy, but systematic epidemiological studies are limited.
The core pathophysiology of tonic-clonic SE is failure of the normal seizure termination mechanisms.
As seizures continue, GABA-A receptors on the postsynaptic membrane are internalized into the cell, reducing the inhibitory effect. This process begins within 20–30 minutes of seizure onset, and it explains why SE that initially responds to treatment becomes treatment-resistant the longer it persists. Therefore, benzodiazepines (GABA-A modulators) are most effective early in SE, and their efficacy declines after 30 minutes or more have elapsed.
As SE persists, NMDA and AMPA receptors move to the synaptic surface (synaptic upregulation), increasing excitatory transmission. Excessive glutamate release causes neuronal injury (excitotoxicity) through calcium overload.
Early seizure phase (first 30 minutes): increased heart rate, elevated blood pressure, elevated blood glucose, lactic acidosis. Late seizure phase (after 30 minutes): hypotension, hypoglycemia, hypoxia, hyperthermia (40℃ or higher), rhabdomyolysis and renal failure develop secondarily. These systemic complications are the main causes of SE-related death.
Tonic-clonic SE shows the following clinical phases.
| Phase | Clinical features | Time |
|---|---|---|
| Tonic phase | Generalized muscle rigidity, upward eye deviation, apnea, cyanosis | 10–30 seconds |
| Clonic phase | Rhythmic limb convulsions, salivation, tongue biting | Tens of seconds to several minutes |
| Postictal phase | Coma with gradual recovery; in SE, recurrence without recovery of consciousness | Several minutes to tens of minutes |
Unlike a simple tonic-clonic seizure, in SE convulsions persist continuously for 5 minutes or longer, or seizures recur without recovery of consciousness between them. Over time, the amplitude of convulsions gradually decreases and shifts to a subtle pattern (subtle SE), which may be difficult to recognize clinically. At this stage, the EEG still shows continuous seizure activity, so EEG monitoring is essential.
Early: generalized or focal continuous spike discharges. Late: burst suppression pattern or persistent slowing. Subtle SE: clinical convulsions are minimal but continuous seizure activity is present on EEG.
Because tonic-clonic SE is an emergency, screening tests and treatment proceed simultaneously.
The diagnosis of tonic-clonic SE is mainly clinical. The criterion is a tonic-clonic seizure lasting 5 minutes or longer, or two or more recurrent seizures without recovery of consciousness between seizures.
Identification of the cause of SE is carried out systematically in parallel with acute treatment. In particular, in new-onset SE in patients without underlying epilepsy, structural, metabolic, infectious and autoimmune causes must be excluded.
In SE in which convulsions gradually become subtle, subtle signs such as eye deviation, fine limb tremor and eyelid twitching may remain. At this point, EEG is essential for diagnosis.
| Phase | Time | Drugs and doses |
|---|---|---|
| Stage 1 (benzodiazepines) | 0–5 minutes | Lorazepam IV 0.1 mg/kg (maximum 4 mg); if no IV, midazolam IM 0.2 mg/kg (10 mg), or rectal diazepam 0.2–0.5 mg/kg |
| Stage 2 (second-line drugs) | 5–20 minutes | Fosphenytoin 20 mg PE/kg IV, or valproic acid 30–40 mg/kg IV, or levetiracetam 60 mg/kg IV (maximum 4,500 mg) |
| Stage 3 (refractory SE) | 20–40 minutes | Continuous midazolam infusion 0.05–0.4 mg/kg/h, or propofol IV (adults), or phenobarbital 15–20 mg/kg IV |
| Stage 4 (super-refractory SE) | >24 hours | Ketamine, inhaled anesthetics (isoflurane), ketogenic diet, immunotherapy (autoimmune causes) |
The prognosis of tonic-clonic SE is determined by the underlying disease, duration of SE, patient age and promptness of treatment.
STESS (Status Epilepticus Severity Score) is a tool used in clinical practice that predicts the risk of death based on level of consciousness, seizure type, age, history of SE and other factors.